Differential effects of glucagon-like peptide-1 receptor agonists on heart rate

Overview of attention for article published in Cardiovascular Diabetology, January 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 3 news outlets
twitter: 4 X users

patent: 2 patents
video: 1 YouTube creator

Citations

dimensions_citation: 106 Dimensions

Readers on

mendeley: 69 Mendeley

Summary News X Patents YouTube Dimensions citations

So far, Altmetric has seen 4 news stories from 3 outlets.

Ozempic, Wegovy under investigation for side effects like suicidal…

Medical News Today, 08 Jan 2024

Share on PinterestThe Food and Drug Administration is investigating possible side effects from GLP-1 drugs, including suicidal…

Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi.

The Free Library, 28 Jun 2023

Byline: Saeeda Fouzia Qasim, Tasnim Ahsan, Saima Ghaus and Paras Imran KEYWORDS: Diabetes Mellitus, GLP-1RA, Obesity, Glycemic…

Ozempic isn't just for weight loss and diabetes. Here are all the conditions it could one day treat — from cancer to addiction.

Yahoo! News, 23 May 2023

Ozempic, a form of the drug semaglutide, was originally approved for type 2 diabetes in 2017.

Ozempic isn't just for weight loss and diabetes. Here are all the conditions it could one day treat — from cancer to addiction.

Yahoo! News, 23 May 2023

Ozempic, a form of the drug semaglutide, was originally approved for type 2 diabetes in 2017.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.